nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluoxetine—ABCB1—kidney cancer	0.144	1	CbGaD
Fluoxetine—ORM1—Erlotinib—kidney cancer	0.0447	0.0801	CbGbCtD
Fluoxetine—CYP3A5—Temsirolimus—kidney cancer	0.0404	0.0723	CbGbCtD
Fluoxetine—ABCB1—Temsirolimus—kidney cancer	0.0263	0.047	CbGbCtD
Fluoxetine—HTR2C—Sorafenib—kidney cancer	0.0252	0.045	CbGbCtD
Fluoxetine—CYP2D6—Temsirolimus—kidney cancer	0.0248	0.0443	CbGbCtD
Fluoxetine—CYP3A4—Everolimus—kidney cancer	0.0233	0.0417	CbGbCtD
Fluoxetine—ALB—Erlotinib—kidney cancer	0.0188	0.0337	CbGbCtD
Fluoxetine—CYP1A2—Pazopanib—kidney cancer	0.0158	0.0282	CbGbCtD
Fluoxetine—CYP3A4—Temsirolimus—kidney cancer	0.0157	0.0282	CbGbCtD
Fluoxetine—CYP2B6—Sorafenib—kidney cancer	0.0156	0.028	CbGbCtD
Fluoxetine—CYP3A5—Erlotinib—kidney cancer	0.0151	0.0271	CbGbCtD
Fluoxetine—CYP2C9—Capecitabine—kidney cancer	0.0148	0.0265	CbGbCtD
Fluoxetine—CYP3A5—Paclitaxel—kidney cancer	0.0139	0.0248	CbGbCtD
Fluoxetine—ABCB1—Pazopanib—kidney cancer	0.0138	0.0247	CbGbCtD
Fluoxetine—CYP2D6—Pazopanib—kidney cancer	0.013	0.0233	CbGbCtD
Fluoxetine—ABCB1—Dactinomycin—kidney cancer	0.0126	0.0226	CbGbCtD
Fluoxetine—CYP3A5—Sorafenib—kidney cancer	0.0123	0.022	CbGbCtD
Fluoxetine—CYP3A5—Vincristine—kidney cancer	0.0119	0.0214	CbGbCtD
Fluoxetine—CYP1A2—Erlotinib—kidney cancer	0.0113	0.0202	CbGbCtD
Fluoxetine—ABCB1—Gemcitabine—kidney cancer	0.00998	0.0179	CbGbCtD
Fluoxetine—CYP3A5—Sunitinib—kidney cancer	0.00997	0.0178	CbGbCtD
Fluoxetine—CYP2C19—Sorafenib—kidney cancer	0.00992	0.0178	CbGbCtD
Fluoxetine—ABCB1—Erlotinib—kidney cancer	0.00985	0.0176	CbGbCtD
Fluoxetine—CYP2B6—Doxorubicin—kidney cancer	0.00948	0.017	CbGbCtD
Fluoxetine—CYP2C9—Paclitaxel—kidney cancer	0.00929	0.0166	CbGbCtD
Fluoxetine—CYP2D6—Erlotinib—kidney cancer	0.00928	0.0166	CbGbCtD
Fluoxetine—CYP1A2—Sorafenib—kidney cancer	0.00916	0.0164	CbGbCtD
Fluoxetine—ABCB1—Paclitaxel—kidney cancer	0.00901	0.0161	CbGbCtD
Fluoxetine—CYP3A4—Pazopanib—kidney cancer	0.00827	0.0148	CbGbCtD
Fluoxetine—CYP2C9—Sorafenib—kidney cancer	0.00825	0.0148	CbGbCtD
Fluoxetine—ABCB1—Sorafenib—kidney cancer	0.00801	0.0143	CbGbCtD
Fluoxetine—ABCB1—Vinblastine—kidney cancer	0.00791	0.0142	CbGbCtD
Fluoxetine—ABCB1—Vincristine—kidney cancer	0.00777	0.0139	CbGbCtD
Fluoxetine—CYP2D6—Sorafenib—kidney cancer	0.00754	0.0135	CbGbCtD
Fluoxetine—CYP2D6—Vinblastine—kidney cancer	0.00745	0.0133	CbGbCtD
Fluoxetine—ABCB1—Sunitinib—kidney cancer	0.00649	0.0116	CbGbCtD
Fluoxetine—CYP3A4—Erlotinib—kidney cancer	0.0059	0.0106	CbGbCtD
Fluoxetine—CYP3A4—Paclitaxel—kidney cancer	0.0054	0.00967	CbGbCtD
Fluoxetine—ABCB1—Doxorubicin—kidney cancer	0.00486	0.0087	CbGbCtD
Fluoxetine—CYP3A4—Sorafenib—kidney cancer	0.0048	0.00859	CbGbCtD
Fluoxetine—CYP3A4—Vinblastine—kidney cancer	0.00474	0.00848	CbGbCtD
Fluoxetine—CYP3A4—Vincristine—kidney cancer	0.00466	0.00834	CbGbCtD
Fluoxetine—CYP2D6—Doxorubicin—kidney cancer	0.00458	0.00819	CbGbCtD
Fluoxetine—CYP3A4—Sunitinib—kidney cancer	0.00389	0.00696	CbGbCtD
Fluoxetine—CYP3A4—Doxorubicin—kidney cancer	0.00291	0.00521	CbGbCtD
Fluoxetine—CYP2C19—urine—kidney cancer	0.00199	0.114	CbGeAlD
Fluoxetine—CYP1A2—urine—kidney cancer	0.00162	0.0934	CbGeAlD
Fluoxetine—CYP2C9—urine—kidney cancer	0.00154	0.0887	CbGeAlD
Fluoxetine—HTR2A—urine—kidney cancer	0.00127	0.073	CbGeAlD
Fluoxetine—CYP3A4—urine—kidney cancer	0.00117	0.0676	CbGeAlD
Fluoxetine—CYP2D6—urine—kidney cancer	0.00116	0.0665	CbGeAlD
Fluoxetine—SIGMAR1—nephron tubule—kidney cancer	0.000641	0.0369	CbGeAlD
Fluoxetine—SIGMAR1—cortex of kidney—kidney cancer	0.000548	0.0316	CbGeAlD
Fluoxetine—SIGMAR1—cardiac atrium—kidney cancer	0.000521	0.03	CbGeAlD
Fluoxetine—SLC6A2—gonad—kidney cancer	0.000463	0.0267	CbGeAlD
Fluoxetine—CYP3A5—nephron tubule—kidney cancer	0.000421	0.0242	CbGeAlD
Fluoxetine—CYP2B6—nephron tubule—kidney cancer	0.000418	0.0241	CbGeAlD
Fluoxetine—CYP1A2—renal system—kidney cancer	0.000397	0.0229	CbGeAlD
Fluoxetine—CYP3A5—renal system—kidney cancer	0.000383	0.022	CbGeAlD
Fluoxetine—CYP2B6—renal system—kidney cancer	0.00038	0.0219	CbGeAlD
Fluoxetine—CYP3A5—kidney—kidney cancer	0.00037	0.0213	CbGeAlD
Fluoxetine—CYP2B6—kidney—kidney cancer	0.000368	0.0212	CbGeAlD
Fluoxetine—CYP3A5—cortex of kidney—kidney cancer	0.00036	0.0208	CbGeAlD
Fluoxetine—CYP2B6—gonad—kidney cancer	0.000341	0.0196	CbGeAlD
Fluoxetine—HTR2A—renal system—kidney cancer	0.00031	0.0179	CbGeAlD
Fluoxetine—HTR2A—kidney—kidney cancer	0.0003	0.0173	CbGeAlD
Fluoxetine—CYP3A4—renal system—kidney cancer	0.000287	0.0165	CbGeAlD
Fluoxetine—CYP2D6—renal system—kidney cancer	0.000283	0.0163	CbGeAlD
Fluoxetine—HTR2A—gonad—kidney cancer	0.000278	0.016	CbGeAlD
Fluoxetine—CYP3A4—kidney—kidney cancer	0.000278	0.016	CbGeAlD
Fluoxetine—CYP2D6—kidney—kidney cancer	0.000273	0.0157	CbGeAlD
Fluoxetine—ABCB1—nephron tubule—kidney cancer	0.000224	0.0129	CbGeAlD
Fluoxetine—ABCB1—renal system—kidney cancer	0.000203	0.0117	CbGeAlD
Fluoxetine—ABCB1—kidney—kidney cancer	0.000197	0.0113	CbGeAlD
Fluoxetine—ABCB1—cortex of kidney—kidney cancer	0.000191	0.011	CbGeAlD
Fluoxetine—ABCB1—gonad—kidney cancer	0.000182	0.0105	CbGeAlD
Fluoxetine—Mood swings—Doxorubicin—kidney cancer	5.16e-05	0.000206	CcSEcCtD
Fluoxetine—Diarrhoea—Sunitinib—kidney cancer	5.15e-05	0.000206	CcSEcCtD
Fluoxetine—Ataxia—Doxorubicin—kidney cancer	5.12e-05	0.000204	CcSEcCtD
Fluoxetine—Mental disorder—Capecitabine—kidney cancer	5.12e-05	0.000204	CcSEcCtD
Fluoxetine—Asthenia—Dactinomycin—kidney cancer	5.11e-05	0.000204	CcSEcCtD
Fluoxetine—Confusional state—Paclitaxel—kidney cancer	5.1e-05	0.000204	CcSEcCtD
Fluoxetine—Malnutrition—Capecitabine—kidney cancer	5.09e-05	0.000203	CcSEcCtD
Fluoxetine—Dehydration—Doxorubicin—kidney cancer	5.06e-05	0.000202	CcSEcCtD
Fluoxetine—Anaphylactic shock—Paclitaxel—kidney cancer	5.06e-05	0.000202	CcSEcCtD
Fluoxetine—Abdominal pain—Vincristine—kidney cancer	5.03e-05	0.000201	CcSEcCtD
Fluoxetine—Body temperature increased—Vincristine—kidney cancer	5.03e-05	0.000201	CcSEcCtD
Fluoxetine—Liver function test abnormal—Doxorubicin—kidney cancer	5.03e-05	0.000201	CcSEcCtD
Fluoxetine—Infection—Paclitaxel—kidney cancer	5.02e-05	0.000201	CcSEcCtD
Fluoxetine—Flatulence—Capecitabine—kidney cancer	5.01e-05	0.0002	CcSEcCtD
Fluoxetine—Dry skin—Doxorubicin—kidney cancer	4.99e-05	0.000199	CcSEcCtD
Fluoxetine—Dysgeusia—Capecitabine—kidney cancer	4.98e-05	0.000199	CcSEcCtD
Fluoxetine—Dizziness—Sunitinib—kidney cancer	4.98e-05	0.000199	CcSEcCtD
Fluoxetine—Feeling abnormal—Gemcitabine—kidney cancer	4.98e-05	0.000199	CcSEcCtD
Fluoxetine—Shock—Paclitaxel—kidney cancer	4.98e-05	0.000199	CcSEcCtD
Fluoxetine—Vomiting—Sorafenib—kidney cancer	4.97e-05	0.000199	CcSEcCtD
Fluoxetine—Orthostatic hypotension—Doxorubicin—kidney cancer	4.97e-05	0.000198	CcSEcCtD
Fluoxetine—Hypokalaemia—Doxorubicin—kidney cancer	4.95e-05	0.000198	CcSEcCtD
Fluoxetine—Thrombocytopenia—Paclitaxel—kidney cancer	4.95e-05	0.000198	CcSEcCtD
Fluoxetine—Tachycardia—Paclitaxel—kidney cancer	4.94e-05	0.000197	CcSEcCtD
Fluoxetine—Rash—Sorafenib—kidney cancer	4.93e-05	0.000197	CcSEcCtD
Fluoxetine—Dermatitis—Sorafenib—kidney cancer	4.93e-05	0.000197	CcSEcCtD
Fluoxetine—Back pain—Capecitabine—kidney cancer	4.92e-05	0.000196	CcSEcCtD
Fluoxetine—Breast disorder—Doxorubicin—kidney cancer	4.92e-05	0.000196	CcSEcCtD
Fluoxetine—Skin disorder—Paclitaxel—kidney cancer	4.91e-05	0.000196	CcSEcCtD
Fluoxetine—Toxic epidermal necrolysis—Doxorubicin—kidney cancer	4.9e-05	0.000196	CcSEcCtD
Fluoxetine—Headache—Sorafenib—kidney cancer	4.9e-05	0.000196	CcSEcCtD
Fluoxetine—Muscle spasms—Capecitabine—kidney cancer	4.89e-05	0.000195	CcSEcCtD
Fluoxetine—Hyperhidrosis—Paclitaxel—kidney cancer	4.89e-05	0.000195	CcSEcCtD
Fluoxetine—Diarrhoea—Dactinomycin—kidney cancer	4.88e-05	0.000195	CcSEcCtD
Fluoxetine—Anorexia—Paclitaxel—kidney cancer	4.82e-05	0.000192	CcSEcCtD
Fluoxetine—Gastritis—Doxorubicin—kidney cancer	4.82e-05	0.000192	CcSEcCtD
Fluoxetine—Muscular weakness—Doxorubicin—kidney cancer	4.8e-05	0.000192	CcSEcCtD
Fluoxetine—Alanine aminotransferase increased—Doxorubicin—kidney cancer	4.8e-05	0.000192	CcSEcCtD
Fluoxetine—Vomiting—Sunitinib—kidney cancer	4.79e-05	0.000191	CcSEcCtD
Fluoxetine—Body temperature increased—Gemcitabine—kidney cancer	4.78e-05	0.000191	CcSEcCtD
Fluoxetine—Tremor—Capecitabine—kidney cancer	4.76e-05	0.00019	CcSEcCtD
Fluoxetine—Rash—Sunitinib—kidney cancer	4.75e-05	0.000189	CcSEcCtD
Fluoxetine—Dermatitis—Sunitinib—kidney cancer	4.74e-05	0.000189	CcSEcCtD
Fluoxetine—Abdominal distension—Doxorubicin—kidney cancer	4.74e-05	0.000189	CcSEcCtD
Fluoxetine—Hypotension—Paclitaxel—kidney cancer	4.73e-05	0.000189	CcSEcCtD
Fluoxetine—Ill-defined disorder—Capecitabine—kidney cancer	4.72e-05	0.000188	CcSEcCtD
Fluoxetine—Headache—Sunitinib—kidney cancer	4.72e-05	0.000188	CcSEcCtD
Fluoxetine—Dysphagia—Doxorubicin—kidney cancer	4.71e-05	0.000188	CcSEcCtD
Fluoxetine—Influenza—Doxorubicin—kidney cancer	4.71e-05	0.000188	CcSEcCtD
Fluoxetine—Asthma—Doxorubicin—kidney cancer	4.71e-05	0.000188	CcSEcCtD
Fluoxetine—Anaemia—Capecitabine—kidney cancer	4.7e-05	0.000188	CcSEcCtD
Fluoxetine—Hypersensitivity—Vincristine—kidney cancer	4.69e-05	0.000187	CcSEcCtD
Fluoxetine—Eosinophilia—Doxorubicin—kidney cancer	4.66e-05	0.000186	CcSEcCtD
Fluoxetine—Nausea—Sorafenib—kidney cancer	4.65e-05	0.000186	CcSEcCtD
Fluoxetine—Pancreatitis—Doxorubicin—kidney cancer	4.61e-05	0.000184	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Paclitaxel—kidney cancer	4.61e-05	0.000184	CcSEcCtD
Fluoxetine—Malaise—Capecitabine—kidney cancer	4.59e-05	0.000183	CcSEcCtD
Fluoxetine—Angina pectoris—Doxorubicin—kidney cancer	4.58e-05	0.000183	CcSEcCtD
Fluoxetine—Insomnia—Paclitaxel—kidney cancer	4.57e-05	0.000183	CcSEcCtD
Fluoxetine—Vertigo—Capecitabine—kidney cancer	4.57e-05	0.000182	CcSEcCtD
Fluoxetine—Asthenia—Vincristine—kidney cancer	4.57e-05	0.000182	CcSEcCtD
Fluoxetine—Syncope—Capecitabine—kidney cancer	4.56e-05	0.000182	CcSEcCtD
Fluoxetine—Leukopenia—Capecitabine—kidney cancer	4.55e-05	0.000182	CcSEcCtD
Fluoxetine—Paraesthesia—Paclitaxel—kidney cancer	4.54e-05	0.000181	CcSEcCtD
Fluoxetine—Vomiting—Dactinomycin—kidney cancer	4.53e-05	0.000181	CcSEcCtD
Fluoxetine—Bronchitis—Doxorubicin—kidney cancer	4.52e-05	0.000181	CcSEcCtD
Fluoxetine—Dyspnoea—Paclitaxel—kidney cancer	4.51e-05	0.00018	CcSEcCtD
Fluoxetine—Somnolence—Paclitaxel—kidney cancer	4.5e-05	0.000179	CcSEcCtD
Fluoxetine—Palpitations—Capecitabine—kidney cancer	4.49e-05	0.000179	CcSEcCtD
Fluoxetine—Rash—Dactinomycin—kidney cancer	4.49e-05	0.000179	CcSEcCtD
Fluoxetine—Nausea—Sunitinib—kidney cancer	4.47e-05	0.000179	CcSEcCtD
Fluoxetine—Loss of consciousness—Capecitabine—kidney cancer	4.47e-05	0.000178	CcSEcCtD
Fluoxetine—Pancytopenia—Doxorubicin—kidney cancer	4.47e-05	0.000178	CcSEcCtD
Fluoxetine—Dyspepsia—Paclitaxel—kidney cancer	4.45e-05	0.000178	CcSEcCtD
Fluoxetine—Cough—Capecitabine—kidney cancer	4.44e-05	0.000177	CcSEcCtD
Fluoxetine—Dysuria—Doxorubicin—kidney cancer	4.4e-05	0.000176	CcSEcCtD
Fluoxetine—Decreased appetite—Paclitaxel—kidney cancer	4.4e-05	0.000176	CcSEcCtD
Fluoxetine—Hypertension—Capecitabine—kidney cancer	4.39e-05	0.000175	CcSEcCtD
Fluoxetine—Upper respiratory tract infection—Doxorubicin—kidney cancer	4.37e-05	0.000175	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Paclitaxel—kidney cancer	4.37e-05	0.000174	CcSEcCtD
Fluoxetine—Fatigue—Paclitaxel—kidney cancer	4.36e-05	0.000174	CcSEcCtD
Fluoxetine—Diarrhoea—Vincristine—kidney cancer	4.36e-05	0.000174	CcSEcCtD
Fluoxetine—Pollakiuria—Doxorubicin—kidney cancer	4.35e-05	0.000173	CcSEcCtD
Fluoxetine—Asthenia—Gemcitabine—kidney cancer	4.33e-05	0.000173	CcSEcCtD
Fluoxetine—Arthralgia—Capecitabine—kidney cancer	4.33e-05	0.000173	CcSEcCtD
Fluoxetine—Chest pain—Capecitabine—kidney cancer	4.33e-05	0.000173	CcSEcCtD
Fluoxetine—Myalgia—Capecitabine—kidney cancer	4.33e-05	0.000173	CcSEcCtD
Fluoxetine—Pain—Paclitaxel—kidney cancer	4.33e-05	0.000173	CcSEcCtD
Fluoxetine—Constipation—Paclitaxel—kidney cancer	4.33e-05	0.000173	CcSEcCtD
Fluoxetine—Anxiety—Capecitabine—kidney cancer	4.31e-05	0.000172	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	4.3e-05	0.000172	CcSEcCtD
Fluoxetine—Photosensitivity reaction—Doxorubicin—kidney cancer	4.29e-05	0.000171	CcSEcCtD
Fluoxetine—Weight increased—Doxorubicin—kidney cancer	4.28e-05	0.000171	CcSEcCtD
Fluoxetine—Discomfort—Capecitabine—kidney cancer	4.28e-05	0.000171	CcSEcCtD
Fluoxetine—Pruritus—Gemcitabine—kidney cancer	4.27e-05	0.000171	CcSEcCtD
Fluoxetine—Weight decreased—Doxorubicin—kidney cancer	4.26e-05	0.00017	CcSEcCtD
Fluoxetine—Hyperglycaemia—Doxorubicin—kidney cancer	4.24e-05	0.000169	CcSEcCtD
Fluoxetine—Dry mouth—Capecitabine—kidney cancer	4.23e-05	0.000169	CcSEcCtD
Fluoxetine—Nausea—Dactinomycin—kidney cancer	4.23e-05	0.000169	CcSEcCtD
Fluoxetine—Pneumonia—Doxorubicin—kidney cancer	4.22e-05	0.000168	CcSEcCtD
Fluoxetine—Dizziness—Vincristine—kidney cancer	4.21e-05	0.000168	CcSEcCtD
Fluoxetine—Drowsiness—Doxorubicin—kidney cancer	4.2e-05	0.000167	CcSEcCtD
Fluoxetine—Confusional state—Capecitabine—kidney cancer	4.19e-05	0.000167	CcSEcCtD
Fluoxetine—Feeling abnormal—Paclitaxel—kidney cancer	4.17e-05	0.000166	CcSEcCtD
Fluoxetine—Stevens-Johnson syndrome—Doxorubicin—kidney cancer	4.16e-05	0.000166	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Paclitaxel—kidney cancer	4.14e-05	0.000165	CcSEcCtD
Fluoxetine—Diarrhoea—Gemcitabine—kidney cancer	4.13e-05	0.000165	CcSEcCtD
Fluoxetine—Renal failure—Doxorubicin—kidney cancer	4.12e-05	0.000165	CcSEcCtD
Fluoxetine—Infection—Capecitabine—kidney cancer	4.12e-05	0.000165	CcSEcCtD
Fluoxetine—Neuropathy peripheral—Doxorubicin—kidney cancer	4.11e-05	0.000164	CcSEcCtD
Fluoxetine—Jaundice—Doxorubicin—kidney cancer	4.09e-05	0.000163	CcSEcCtD
Fluoxetine—Stomatitis—Doxorubicin—kidney cancer	4.09e-05	0.000163	CcSEcCtD
Fluoxetine—Shock—Capecitabine—kidney cancer	4.08e-05	0.000163	CcSEcCtD
Fluoxetine—Conjunctivitis—Doxorubicin—kidney cancer	4.08e-05	0.000163	CcSEcCtD
Fluoxetine—Urinary tract infection—Doxorubicin—kidney cancer	4.08e-05	0.000163	CcSEcCtD
Fluoxetine—Thrombocytopenia—Capecitabine—kidney cancer	4.06e-05	0.000162	CcSEcCtD
Fluoxetine—Tachycardia—Capecitabine—kidney cancer	4.05e-05	0.000162	CcSEcCtD
Fluoxetine—Vomiting—Vincristine—kidney cancer	4.05e-05	0.000162	CcSEcCtD
Fluoxetine—Skin disorder—Capecitabine—kidney cancer	4.03e-05	0.000161	CcSEcCtD
Fluoxetine—Sweating—Doxorubicin—kidney cancer	4.02e-05	0.000161	CcSEcCtD
Fluoxetine—Urticaria—Paclitaxel—kidney cancer	4.02e-05	0.00016	CcSEcCtD
Fluoxetine—Rash—Vincristine—kidney cancer	4.02e-05	0.00016	CcSEcCtD
Fluoxetine—Hyperhidrosis—Capecitabine—kidney cancer	4.01e-05	0.00016	CcSEcCtD
Fluoxetine—Dermatitis—Vincristine—kidney cancer	4.01e-05	0.00016	CcSEcCtD
Fluoxetine—Haematuria—Doxorubicin—kidney cancer	4e-05	0.00016	CcSEcCtD
Fluoxetine—Abdominal pain—Paclitaxel—kidney cancer	4e-05	0.00016	CcSEcCtD
Fluoxetine—Body temperature increased—Paclitaxel—kidney cancer	4e-05	0.00016	CcSEcCtD
Fluoxetine—Headache—Vincristine—kidney cancer	3.99e-05	0.000159	CcSEcCtD
Fluoxetine—Epistaxis—Doxorubicin—kidney cancer	3.96e-05	0.000158	CcSEcCtD
Fluoxetine—Anorexia—Capecitabine—kidney cancer	3.96e-05	0.000158	CcSEcCtD
Fluoxetine—Sinusitis—Doxorubicin—kidney cancer	3.94e-05	0.000157	CcSEcCtD
Fluoxetine—Hypotension—Capecitabine—kidney cancer	3.88e-05	0.000155	CcSEcCtD
Fluoxetine—Vomiting—Gemcitabine—kidney cancer	3.84e-05	0.000153	CcSEcCtD
Fluoxetine—Bradycardia—Doxorubicin—kidney cancer	3.83e-05	0.000153	CcSEcCtD
Fluoxetine—Rash—Gemcitabine—kidney cancer	3.81e-05	0.000152	CcSEcCtD
Fluoxetine—Dermatitis—Gemcitabine—kidney cancer	3.81e-05	0.000152	CcSEcCtD
Fluoxetine—Haemoglobin—Doxorubicin—kidney cancer	3.79e-05	0.000151	CcSEcCtD
Fluoxetine—Headache—Gemcitabine—kidney cancer	3.78e-05	0.000151	CcSEcCtD
Fluoxetine—Nausea—Vincristine—kidney cancer	3.78e-05	0.000151	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Capecitabine—kidney cancer	3.78e-05	0.000151	CcSEcCtD
Fluoxetine—Rhinitis—Doxorubicin—kidney cancer	3.78e-05	0.000151	CcSEcCtD
Fluoxetine—Haemorrhage—Doxorubicin—kidney cancer	3.77e-05	0.00015	CcSEcCtD
Fluoxetine—Hepatitis—Doxorubicin—kidney cancer	3.77e-05	0.00015	CcSEcCtD
Fluoxetine—Insomnia—Capecitabine—kidney cancer	3.75e-05	0.00015	CcSEcCtD
Fluoxetine—Hypoaesthesia—Doxorubicin—kidney cancer	3.75e-05	0.00015	CcSEcCtD
Fluoxetine—Pharyngitis—Doxorubicin—kidney cancer	3.74e-05	0.000149	CcSEcCtD
Fluoxetine—Paraesthesia—Capecitabine—kidney cancer	3.73e-05	0.000149	CcSEcCtD
Fluoxetine—Hypersensitivity—Paclitaxel—kidney cancer	3.73e-05	0.000149	CcSEcCtD
Fluoxetine—Oedema peripheral—Doxorubicin—kidney cancer	3.71e-05	0.000148	CcSEcCtD
Fluoxetine—Dyspnoea—Capecitabine—kidney cancer	3.7e-05	0.000148	CcSEcCtD
Fluoxetine—Dyspepsia—Capecitabine—kidney cancer	3.65e-05	0.000146	CcSEcCtD
Fluoxetine—Visual impairment—Doxorubicin—kidney cancer	3.63e-05	0.000145	CcSEcCtD
Fluoxetine—Asthenia—Paclitaxel—kidney cancer	3.63e-05	0.000145	CcSEcCtD
Fluoxetine—Decreased appetite—Capecitabine—kidney cancer	3.61e-05	0.000144	CcSEcCtD
Fluoxetine—Nausea—Gemcitabine—kidney cancer	3.59e-05	0.000143	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Capecitabine—kidney cancer	3.58e-05	0.000143	CcSEcCtD
Fluoxetine—Fatigue—Capecitabine—kidney cancer	3.58e-05	0.000143	CcSEcCtD
Fluoxetine—Pruritus—Paclitaxel—kidney cancer	3.58e-05	0.000143	CcSEcCtD
Fluoxetine—Erythema multiforme—Doxorubicin—kidney cancer	3.56e-05	0.000142	CcSEcCtD
Fluoxetine—Pain—Capecitabine—kidney cancer	3.55e-05	0.000142	CcSEcCtD
Fluoxetine—Constipation—Capecitabine—kidney cancer	3.55e-05	0.000142	CcSEcCtD
Fluoxetine—Tinnitus—Doxorubicin—kidney cancer	3.51e-05	0.00014	CcSEcCtD
Fluoxetine—Diarrhoea—Paclitaxel—kidney cancer	3.46e-05	0.000138	CcSEcCtD
Fluoxetine—Feeling abnormal—Capecitabine—kidney cancer	3.42e-05	0.000137	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Capecitabine—kidney cancer	3.39e-05	0.000135	CcSEcCtD
Fluoxetine—Chills—Doxorubicin—kidney cancer	3.38e-05	0.000135	CcSEcCtD
Fluoxetine—Arrhythmia—Doxorubicin—kidney cancer	3.36e-05	0.000134	CcSEcCtD
Fluoxetine—Dizziness—Paclitaxel—kidney cancer	3.34e-05	0.000134	CcSEcCtD
Fluoxetine—Alopecia—Doxorubicin—kidney cancer	3.33e-05	0.000133	CcSEcCtD
Fluoxetine—Mental disorder—Doxorubicin—kidney cancer	3.3e-05	0.000132	CcSEcCtD
Fluoxetine—Urticaria—Capecitabine—kidney cancer	3.3e-05	0.000132	CcSEcCtD
Fluoxetine—Abdominal pain—Capecitabine—kidney cancer	3.28e-05	0.000131	CcSEcCtD
Fluoxetine—Body temperature increased—Capecitabine—kidney cancer	3.28e-05	0.000131	CcSEcCtD
Fluoxetine—Malnutrition—Doxorubicin—kidney cancer	3.28e-05	0.000131	CcSEcCtD
Fluoxetine—Flatulence—Doxorubicin—kidney cancer	3.23e-05	0.000129	CcSEcCtD
Fluoxetine—Tension—Doxorubicin—kidney cancer	3.22e-05	0.000128	CcSEcCtD
Fluoxetine—Vomiting—Paclitaxel—kidney cancer	3.22e-05	0.000128	CcSEcCtD
Fluoxetine—Dysgeusia—Doxorubicin—kidney cancer	3.21e-05	0.000128	CcSEcCtD
Fluoxetine—Rash—Paclitaxel—kidney cancer	3.19e-05	0.000127	CcSEcCtD
Fluoxetine—Dermatitis—Paclitaxel—kidney cancer	3.19e-05	0.000127	CcSEcCtD
Fluoxetine—Nervousness—Doxorubicin—kidney cancer	3.18e-05	0.000127	CcSEcCtD
Fluoxetine—Back pain—Doxorubicin—kidney cancer	3.17e-05	0.000127	CcSEcCtD
Fluoxetine—Headache—Paclitaxel—kidney cancer	3.17e-05	0.000126	CcSEcCtD
Fluoxetine—Muscle spasms—Doxorubicin—kidney cancer	3.15e-05	0.000126	CcSEcCtD
Fluoxetine—Hypersensitivity—Capecitabine—kidney cancer	3.06e-05	0.000122	CcSEcCtD
Fluoxetine—Ill-defined disorder—Doxorubicin—kidney cancer	3.04e-05	0.000121	CcSEcCtD
Fluoxetine—Anaemia—Doxorubicin—kidney cancer	3.03e-05	0.000121	CcSEcCtD
Fluoxetine—Agitation—Doxorubicin—kidney cancer	3.01e-05	0.00012	CcSEcCtD
Fluoxetine—Nausea—Paclitaxel—kidney cancer	3e-05	0.00012	CcSEcCtD
Fluoxetine—Asthenia—Capecitabine—kidney cancer	2.98e-05	0.000119	CcSEcCtD
Fluoxetine—Malaise—Doxorubicin—kidney cancer	2.96e-05	0.000118	CcSEcCtD
Fluoxetine—Vertigo—Doxorubicin—kidney cancer	2.95e-05	0.000118	CcSEcCtD
Fluoxetine—Syncope—Doxorubicin—kidney cancer	2.94e-05	0.000117	CcSEcCtD
Fluoxetine—Pruritus—Capecitabine—kidney cancer	2.94e-05	0.000117	CcSEcCtD
Fluoxetine—Leukopenia—Doxorubicin—kidney cancer	2.93e-05	0.000117	CcSEcCtD
Fluoxetine—Palpitations—Doxorubicin—kidney cancer	2.9e-05	0.000116	CcSEcCtD
Fluoxetine—Loss of consciousness—Doxorubicin—kidney cancer	2.88e-05	0.000115	CcSEcCtD
Fluoxetine—Cough—Doxorubicin—kidney cancer	2.86e-05	0.000114	CcSEcCtD
Fluoxetine—Convulsion—Doxorubicin—kidney cancer	2.84e-05	0.000113	CcSEcCtD
Fluoxetine—Diarrhoea—Capecitabine—kidney cancer	2.84e-05	0.000113	CcSEcCtD
Fluoxetine—Hypertension—Doxorubicin—kidney cancer	2.83e-05	0.000113	CcSEcCtD
Fluoxetine—Arthralgia—Doxorubicin—kidney cancer	2.79e-05	0.000111	CcSEcCtD
Fluoxetine—Myalgia—Doxorubicin—kidney cancer	2.79e-05	0.000111	CcSEcCtD
Fluoxetine—Chest pain—Doxorubicin—kidney cancer	2.79e-05	0.000111	CcSEcCtD
Fluoxetine—Anxiety—Doxorubicin—kidney cancer	2.78e-05	0.000111	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	2.77e-05	0.000111	CcSEcCtD
Fluoxetine—Discomfort—Doxorubicin—kidney cancer	2.76e-05	0.00011	CcSEcCtD
Fluoxetine—Dizziness—Capecitabine—kidney cancer	2.74e-05	0.00011	CcSEcCtD
Fluoxetine—Dry mouth—Doxorubicin—kidney cancer	2.73e-05	0.000109	CcSEcCtD
Fluoxetine—Confusional state—Doxorubicin—kidney cancer	2.7e-05	0.000108	CcSEcCtD
Fluoxetine—Anaphylactic shock—Doxorubicin—kidney cancer	2.68e-05	0.000107	CcSEcCtD
Fluoxetine—Infection—Doxorubicin—kidney cancer	2.66e-05	0.000106	CcSEcCtD
Fluoxetine—Vomiting—Capecitabine—kidney cancer	2.64e-05	0.000105	CcSEcCtD
Fluoxetine—Shock—Doxorubicin—kidney cancer	2.63e-05	0.000105	CcSEcCtD
Fluoxetine—Thrombocytopenia—Doxorubicin—kidney cancer	2.62e-05	0.000105	CcSEcCtD
Fluoxetine—Rash—Capecitabine—kidney cancer	2.62e-05	0.000104	CcSEcCtD
Fluoxetine—Dermatitis—Capecitabine—kidney cancer	2.61e-05	0.000104	CcSEcCtD
Fluoxetine—Tachycardia—Doxorubicin—kidney cancer	2.61e-05	0.000104	CcSEcCtD
Fluoxetine—Headache—Capecitabine—kidney cancer	2.6e-05	0.000104	CcSEcCtD
Fluoxetine—Skin disorder—Doxorubicin—kidney cancer	2.6e-05	0.000104	CcSEcCtD
Fluoxetine—Hyperhidrosis—Doxorubicin—kidney cancer	2.59e-05	0.000103	CcSEcCtD
Fluoxetine—Anorexia—Doxorubicin—kidney cancer	2.55e-05	0.000102	CcSEcCtD
Fluoxetine—Hypotension—Doxorubicin—kidney cancer	2.5e-05	9.98e-05	CcSEcCtD
Fluoxetine—Nausea—Capecitabine—kidney cancer	2.47e-05	9.84e-05	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Doxorubicin—kidney cancer	2.44e-05	9.73e-05	CcSEcCtD
Fluoxetine—Insomnia—Doxorubicin—kidney cancer	2.42e-05	9.66e-05	CcSEcCtD
Fluoxetine—Paraesthesia—Doxorubicin—kidney cancer	2.4e-05	9.59e-05	CcSEcCtD
Fluoxetine—Dyspnoea—Doxorubicin—kidney cancer	2.39e-05	9.52e-05	CcSEcCtD
Fluoxetine—Somnolence—Doxorubicin—kidney cancer	2.38e-05	9.49e-05	CcSEcCtD
Fluoxetine—Dyspepsia—Doxorubicin—kidney cancer	2.36e-05	9.4e-05	CcSEcCtD
Fluoxetine—Decreased appetite—Doxorubicin—kidney cancer	2.33e-05	9.28e-05	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Doxorubicin—kidney cancer	2.31e-05	9.22e-05	CcSEcCtD
Fluoxetine—Fatigue—Doxorubicin—kidney cancer	2.31e-05	9.21e-05	CcSEcCtD
Fluoxetine—Pain—Doxorubicin—kidney cancer	2.29e-05	9.13e-05	CcSEcCtD
Fluoxetine—Constipation—Doxorubicin—kidney cancer	2.29e-05	9.13e-05	CcSEcCtD
Fluoxetine—Feeling abnormal—Doxorubicin—kidney cancer	2.2e-05	8.8e-05	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Doxorubicin—kidney cancer	2.19e-05	8.73e-05	CcSEcCtD
Fluoxetine—Urticaria—Doxorubicin—kidney cancer	2.13e-05	8.48e-05	CcSEcCtD
Fluoxetine—Body temperature increased—Doxorubicin—kidney cancer	2.12e-05	8.44e-05	CcSEcCtD
Fluoxetine—Abdominal pain—Doxorubicin—kidney cancer	2.12e-05	8.44e-05	CcSEcCtD
Fluoxetine—Hypersensitivity—Doxorubicin—kidney cancer	1.97e-05	7.87e-05	CcSEcCtD
Fluoxetine—Asthenia—Doxorubicin—kidney cancer	1.92e-05	7.66e-05	CcSEcCtD
Fluoxetine—Pruritus—Doxorubicin—kidney cancer	1.89e-05	7.56e-05	CcSEcCtD
Fluoxetine—Diarrhoea—Doxorubicin—kidney cancer	1.83e-05	7.31e-05	CcSEcCtD
Fluoxetine—Dizziness—Doxorubicin—kidney cancer	1.77e-05	7.06e-05	CcSEcCtD
Fluoxetine—Vomiting—Doxorubicin—kidney cancer	1.7e-05	6.79e-05	CcSEcCtD
Fluoxetine—Rash—Doxorubicin—kidney cancer	1.69e-05	6.73e-05	CcSEcCtD
Fluoxetine—Dermatitis—Doxorubicin—kidney cancer	1.69e-05	6.73e-05	CcSEcCtD
Fluoxetine—Headache—Doxorubicin—kidney cancer	1.68e-05	6.69e-05	CcSEcCtD
Fluoxetine—Nausea—Doxorubicin—kidney cancer	1.59e-05	6.34e-05	CcSEcCtD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—kidney cancer	6.72e-06	0.000227	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—ACHE—kidney cancer	6.68e-06	0.000225	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—GSTT1—kidney cancer	6.68e-06	0.000225	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—SLC5A5—kidney cancer	6.67e-06	0.000225	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CA2—kidney cancer	6.6e-06	0.000223	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—SLC2A1—kidney cancer	6.59e-06	0.000223	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—ITPR2—kidney cancer	6.57e-06	0.000222	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—POMC—kidney cancer	6.53e-06	0.00022	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—CRABP1—kidney cancer	6.5e-06	0.00022	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—CA9—kidney cancer	6.48e-06	0.000219	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—CRABP1—kidney cancer	6.45e-06	0.000218	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—SLC2A1—kidney cancer	6.44e-06	0.000218	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—ALAD—kidney cancer	6.43e-06	0.000217	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—ITPR2—kidney cancer	6.42e-06	0.000217	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PAK1—kidney cancer	6.41e-06	0.000217	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—JUNB—kidney cancer	6.41e-06	0.000217	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	6.33e-06	0.000214	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—SCARB1—kidney cancer	6.32e-06	0.000213	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—ST3GAL2—kidney cancer	6.28e-06	0.000212	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PTGS1—kidney cancer	6.26e-06	0.000211	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PSMD7—kidney cancer	6.14e-06	0.000207	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—ALDH1A1—kidney cancer	6.13e-06	0.000207	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—RAF1—kidney cancer	6.11e-06	0.000206	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—POMC—kidney cancer	6.06e-06	0.000205	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—ITPR2—kidney cancer	6.05e-06	0.000204	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—IGF2—kidney cancer	6.04e-06	0.000204	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CDKN2B—kidney cancer	6.01e-06	0.000203	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—GSTT1—kidney cancer	5.99e-06	0.000202	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—ACHE—kidney cancer	5.99e-06	0.000202	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—ITPR2—kidney cancer	5.99e-06	0.000202	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—POMC—kidney cancer	5.93e-06	0.0002	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PGK1—kidney cancer	5.88e-06	0.000199	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—SLC5A3—kidney cancer	5.88e-06	0.000199	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—GSTT1—kidney cancer	5.85e-06	0.000198	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—ACHE—kidney cancer	5.85e-06	0.000198	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—IGF1R—kidney cancer	5.84e-06	0.000197	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—BCHE—kidney cancer	5.82e-06	0.000196	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—LDHB—kidney cancer	5.77e-06	0.000195	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—SLC5A5—kidney cancer	5.75e-06	0.000194	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—SCARB1—kidney cancer	5.67e-06	0.000192	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—RAF1—kidney cancer	5.63e-06	0.00019	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PTGS1—kidney cancer	5.62e-06	0.00019	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—IL2—kidney cancer	5.56e-06	0.000188	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—SLC2A1—kidney cancer	5.55e-06	0.000187	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—SCARB1—kidney cancer	5.54e-06	0.000187	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—POMC—kidney cancer	5.52e-06	0.000187	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—ACHE—kidney cancer	5.51e-06	0.000186	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—GSTT1—kidney cancer	5.51e-06	0.000186	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—CRABP1—kidney cancer	5.51e-06	0.000186	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PSMD7—kidney cancer	5.51e-06	0.000186	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—GSTP1—kidney cancer	5.5e-06	0.000186	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PTGS1—kidney cancer	5.48e-06	0.000185	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—IL2—kidney cancer	5.48e-06	0.000185	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—ACHE—kidney cancer	5.47e-06	0.000185	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—GSTT1—kidney cancer	5.47e-06	0.000185	CbGpPWpGaD
Fluoxetine—ALB—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	5.38e-06	0.000182	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PSMD7—kidney cancer	5.38e-06	0.000182	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—GSTP1—kidney cancer	5.37e-06	0.000181	CbGpPWpGaD
Fluoxetine—ALB—Transmembrane transport of small molecules—RAF1—kidney cancer	5.29e-06	0.000179	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—IGF2—kidney cancer	5.24e-06	0.000177	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CDKN2B—kidney cancer	5.22e-06	0.000176	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—BCHE—kidney cancer	5.22e-06	0.000176	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—SCARB1—kidney cancer	5.22e-06	0.000176	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—ABCB1—kidney cancer	5.2e-06	0.000176	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—SCARB1—kidney cancer	5.17e-06	0.000175	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PTGS1—kidney cancer	5.17e-06	0.000174	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—SLC5A5—kidney cancer	5.16e-06	0.000174	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—ITPR2—kidney cancer	5.12e-06	0.000173	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PTGS1—kidney cancer	5.12e-06	0.000173	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—BCHE—kidney cancer	5.1e-06	0.000172	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—ABCB1—kidney cancer	5.09e-06	0.000172	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—IGF1R—kidney cancer	5.07e-06	0.000171	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PSMD7—kidney cancer	5.07e-06	0.000171	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—GSTM1—kidney cancer	5.05e-06	0.000171	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—IL2—kidney cancer	5.04e-06	0.00017	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—SLC5A5—kidney cancer	5.03e-06	0.00017	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PSMD7—kidney cancer	5.02e-06	0.00017	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CA9—kidney cancer	5e-06	0.000169	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—SLC2A1—kidney cancer	4.98e-06	0.000168	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—GSTM1—kidney cancer	4.94e-06	0.000167	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—RAF1—kidney cancer	4.89e-06	0.000165	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—SLC2A1—kidney cancer	4.86e-06	0.000164	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	4.83e-06	0.000163	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—IL2—kidney cancer	4.82e-06	0.000163	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—HIF1A—kidney cancer	4.81e-06	0.000162	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—BCHE—kidney cancer	4.8e-06	0.000162	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—TSC2—kidney cancer	4.8e-06	0.000162	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—CYP1A1—kidney cancer	4.79e-06	0.000162	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—BCHE—kidney cancer	4.76e-06	0.000161	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—SLC5A5—kidney cancer	4.74e-06	0.00016	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—POMC—kidney cancer	4.72e-06	0.000159	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—SLC5A5—kidney cancer	4.7e-06	0.000159	CbGpPWpGaD
Fluoxetine—ALB—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	4.7e-06	0.000159	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—CYP1A1—kidney cancer	4.68e-06	0.000158	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—GSTT1—kidney cancer	4.67e-06	0.000158	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—ACHE—kidney cancer	4.67e-06	0.000158	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—VEGFA—kidney cancer	4.66e-06	0.000157	CbGpPWpGaD
Fluoxetine—ABCB1—Transmembrane transport of small molecules—RAF1—kidney cancer	4.64e-06	0.000157	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—GSTP1—kidney cancer	4.63e-06	0.000156	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—KDR—kidney cancer	4.6e-06	0.000155	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—SLC2A1—kidney cancer	4.58e-06	0.000155	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—SLC2A1—kidney cancer	4.54e-06	0.000153	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—SCARB1—kidney cancer	4.42e-06	0.000149	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	4.41e-06	0.000149	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—MAPK3—kidney cancer	4.41e-06	0.000149	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—IL2—kidney cancer	4.38e-06	0.000148	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—ABCB1—kidney cancer	4.38e-06	0.000148	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PTGS1—kidney cancer	4.38e-06	0.000148	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PSMD7—kidney cancer	4.29e-06	0.000145	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—GSTM1—kidney cancer	4.25e-06	0.000144	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CRABP1—kidney cancer	4.25e-06	0.000144	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—APC—kidney cancer	4.24e-06	0.000143	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—KIT—kidney cancer	4.24e-06	0.000143	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	4.21e-06	0.000142	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—MAPK1—kidney cancer	4.19e-06	0.000142	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—HIF1A—kidney cancer	4.17e-06	0.000141	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—TSC2—kidney cancer	4.16e-06	0.000141	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—GSTP1—kidney cancer	4.15e-06	0.00014	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—BCHE—kidney cancer	4.07e-06	0.000137	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—MAPK3—kidney cancer	4.06e-06	0.000137	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—GSTP1—kidney cancer	4.05e-06	0.000137	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—CYP1A1—kidney cancer	4.03e-06	0.000136	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—POMC—kidney cancer	4.03e-06	0.000136	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—SLC5A5—kidney cancer	4.02e-06	0.000136	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—KDR—kidney cancer	3.99e-06	0.000135	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—BRAF—kidney cancer	3.98e-06	0.000134	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—KRAS—kidney cancer	3.96e-06	0.000134	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—ITPR2—kidney cancer	3.95e-06	0.000133	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—ABCB1—kidney cancer	3.93e-06	0.000133	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—SLC2A1—kidney cancer	3.88e-06	0.000131	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—MAPK1—kidney cancer	3.86e-06	0.00013	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	3.84e-06	0.00013	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—GSTP1—kidney cancer	3.82e-06	0.000129	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—GSTM1—kidney cancer	3.82e-06	0.000129	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—GSTP1—kidney cancer	3.79e-06	0.000128	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	3.77e-06	0.000127	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—GSTM1—kidney cancer	3.73e-06	0.000126	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—PIK3CA—kidney cancer	3.69e-06	0.000125	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—APC—kidney cancer	3.68e-06	0.000124	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—KIT—kidney cancer	3.68e-06	0.000124	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—KRAS—kidney cancer	3.64e-06	0.000123	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—PIK3CA—kidney cancer	3.64e-06	0.000123	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—CYP1A1—kidney cancer	3.62e-06	0.000122	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—ABCB1—kidney cancer	3.62e-06	0.000122	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—ACHE—kidney cancer	3.6e-06	0.000122	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—GSTT1—kidney cancer	3.6e-06	0.000122	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—ABCB1—kidney cancer	3.59e-06	0.000121	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—POMC—kidney cancer	3.57e-06	0.000121	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—CYP1A1—kidney cancer	3.53e-06	0.000119	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—MAPK3—kidney cancer	3.52e-06	0.000119	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—TP53—kidney cancer	3.52e-06	0.000119	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—GSTM1—kidney cancer	3.51e-06	0.000119	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—POMC—kidney cancer	3.5e-06	0.000118	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—POMC—kidney cancer	3.49e-06	0.000118	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—GSTM1—kidney cancer	3.48e-06	0.000118	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—BRAF—kidney cancer	3.46e-06	0.000117	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—SCARB1—kidney cancer	3.41e-06	0.000115	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PTGS1—kidney cancer	3.38e-06	0.000114	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—MAPK1—kidney cancer	3.35e-06	0.000113	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—PIK3CA—kidney cancer	3.35e-06	0.000113	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—CYP1A1—kidney cancer	3.33e-06	0.000112	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—RAF1—kidney cancer	3.32e-06	0.000112	CbGpPWpGaD
Fluoxetine—ALB—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	3.31e-06	0.000112	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PSMD7—kidney cancer	3.31e-06	0.000112	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—RELA—kidney cancer	3.31e-06	0.000112	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—CYP1A1—kidney cancer	3.3e-06	0.000111	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—ERBB2—kidney cancer	3.29e-06	0.000111	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	3.28e-06	0.000111	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MTOR—kidney cancer	3.25e-06	0.00011	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—GSTP1—kidney cancer	3.24e-06	0.000109	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—PIK3CA—kidney cancer	3.2e-06	0.000108	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—KRAS—kidney cancer	3.17e-06	0.000107	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—BCHE—kidney cancer	3.14e-06	0.000106	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—SLC5A5—kidney cancer	3.1e-06	0.000105	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—ABCB1—kidney cancer	3.06e-06	0.000103	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CDKN1B—kidney cancer	3.05e-06	0.000103	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—POMC—kidney cancer	3.01e-06	0.000102	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—SLC2A1—kidney cancer	3e-06	0.000101	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—IL2—kidney cancer	2.98e-06	0.000101	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—GSTM1—kidney cancer	2.97e-06	0.0001	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	2.97e-06	0.0001	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—PIK3CA—kidney cancer	2.91e-06	9.82e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CCND1—kidney cancer	2.91e-06	9.81e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—JUN—kidney cancer	2.9e-06	9.79e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—RAF1—kidney cancer	2.89e-06	9.75e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CTNNB1—kidney cancer	2.88e-06	9.72e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—RELA—kidney cancer	2.87e-06	9.7e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—ERBB2—kidney cancer	2.86e-06	9.64e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PTGS2—kidney cancer	2.85e-06	9.62e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—CYP1A1—kidney cancer	2.82e-06	9.52e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MTOR—kidney cancer	2.82e-06	9.52e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PTEN—kidney cancer	2.8e-06	9.47e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PTGS2—kidney cancer	2.78e-06	9.4e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	2.71e-06	9.16e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—POMC—kidney cancer	2.7e-06	9.11e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CDKN1B—kidney cancer	2.64e-06	8.93e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—POMC—kidney cancer	2.63e-06	8.89e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—IL2—kidney cancer	2.59e-06	8.74e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—VEGFA—kidney cancer	2.53e-06	8.55e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CCND1—kidney cancer	2.52e-06	8.52e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—JUN—kidney cancer	2.52e-06	8.5e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CTNNB1—kidney cancer	2.5e-06	8.44e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—GSTP1—kidney cancer	2.5e-06	8.44e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PTEN—kidney cancer	2.48e-06	8.39e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—POMC—kidney cancer	2.48e-06	8.38e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—POMC—kidney cancer	2.46e-06	8.31e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PTEN—kidney cancer	2.44e-06	8.22e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PTEN—kidney cancer	2.43e-06	8.2e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PTGS2—kidney cancer	2.4e-06	8.1e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MAPK3—kidney cancer	2.4e-06	8.09e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—ABCB1—kidney cancer	2.36e-06	7.99e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MYC—kidney cancer	2.33e-06	7.87e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	2.32e-06	7.82e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—GSTM1—kidney cancer	2.3e-06	7.75e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MAPK1—kidney cancer	2.28e-06	7.7e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—VEGFA—kidney cancer	2.2e-06	7.43e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CYP1A1—kidney cancer	2.18e-06	7.35e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—KRAS—kidney cancer	2.15e-06	7.27e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PTGS2—kidney cancer	2.15e-06	7.27e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—POMC—kidney cancer	2.1e-06	7.1e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PTGS2—kidney cancer	2.1e-06	7.09e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PTEN—kidney cancer	2.09e-06	7.06e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MAPK3—kidney cancer	2.08e-06	7.03e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MYC—kidney cancer	2.02e-06	6.83e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MAPK1—kidney cancer	1.98e-06	6.69e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PTGS2—kidney cancer	1.98e-06	6.69e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PIK3CA—kidney cancer	1.98e-06	6.68e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PTGS2—kidney cancer	1.96e-06	6.63e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—TP53—kidney cancer	1.91e-06	6.46e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PTEN—kidney cancer	1.88e-06	6.34e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—KRAS—kidney cancer	1.87e-06	6.31e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PTEN—kidney cancer	1.83e-06	6.19e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PIK3CA—kidney cancer	1.75e-06	5.92e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PTEN—kidney cancer	1.73e-06	5.83e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PIK3CA—kidney cancer	1.72e-06	5.8e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PIK3CA—kidney cancer	1.71e-06	5.78e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PTEN—kidney cancer	1.71e-06	5.78e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PTGS2—kidney cancer	1.68e-06	5.66e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—TP53—kidney cancer	1.66e-06	5.61e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—POMC—kidney cancer	1.62e-06	5.48e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PIK3CA—kidney cancer	1.48e-06	4.98e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PTEN—kidney cancer	1.46e-06	4.94e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PIK3CA—kidney cancer	1.32e-06	4.47e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PTGS2—kidney cancer	1.29e-06	4.37e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PIK3CA—kidney cancer	1.29e-06	4.36e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PIK3CA—kidney cancer	1.22e-06	4.11e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PIK3CA—kidney cancer	1.21e-06	4.08e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PTEN—kidney cancer	1.13e-06	3.81e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PIK3CA—kidney cancer	1.03e-06	3.48e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PIK3CA—kidney cancer	7.96e-07	2.69e-05	CbGpPWpGaD
